Shanghai Henlius Biotech (HKG:2696) dosed the first patient in a phase 2 clinical study of HLX43 for injection in Spain, according to a Thursday filing with the Hong Kong bourse.
The study aims to evaluate the drug in patients with advanced non-small cell lung cancer.
The phase 2 trial is also ongoing in Mainland China, the U.S., Australia, and Japan.
Bosch's (NSE:BOSCHLTD, BOM:500530) consolidated net profit rose to 5.70 billion Indian rupees in the fiscal fourth quarter ended March 31, from 5.54 billion rupees a year ago.Earnings per share grew to 193.25 rupees from 187.66 rupees a year earlier, the engineering and technology company said in a filing to the Indian stock exchanges on Wednesday.Revenue from operations in fiscal Q4 also increased to 55.7 billion rupees from 49.1 billion rupees a year ago.The company's board recommended a final dividend of 270 rupees per equity share of 10 rupees each for the financial year 2025-26.
HashKey (HKG:3887) said a fund managed by its asset management arm led the Series B+ investment of crypto derivatives platform SignalPlus, according to a Wednesday Hong Kong bourse filing.Shares of the licensed digital asset platform provider were down nearly 2% in late morning trade on Thursday.HashKey Fintech Multi-Strategy Fund IV LP invested $40 million into SignalPlus, $20 million of which came from the group, the filing said.The investment is part of the long-term partnership between both parties, HashKey said.
Youzan Technology (HKG:6051) proposed a 20-to-1 share consolidation and a change in board lot size, according to a Wednesday Hong Kong bourse filing.Shares of the firm were down 18% in Thursday's late morning trade.Under the plan, the company will change the board lot size from 4,000 existing shares to 5,000 consolidated shares.Assuming no further share issuance or repurchases, the number of issued shares will be reduced to about 1.65 billion from about 33 billion following the consolidation.The company said the move is intended to comply with Hong Kong listing requirements and bring the trading value per board lot to a reasonable level to attract a broader investor base, including institutional investors.The share consolidation is subject to shareholder approval at an annual general meeting scheduled for June 30 and is expected to take effect on July 3.